Trial Profile
Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects With Advanced Hepatocellular Carcinoma - A Phase II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 17 Apr 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 17 Apr 2024 Status changed from recruiting to active, no longer recruiting.